No long-term benefit of adding ipilimumab to pembrolizumab in metastatic NSCLC

No long-term benefit of adding ipilimumab to pembrolizumab in metastatic NSCLC

Presented By

Dr Delvys Rodriguez-Abreu, Universidad de Las Palmas de Gran Canaria, Spain

Trial

Phase 3, KEYNOTE-598

Conference

ELCC 2022

25 May, 2022 12:38

ELCC 2022 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ELCC 2022

19 April, 2022 10:43

Adding lenvatinib to pembrolizumab does not improve survival in advanced urothelial carcinoma

Presented By

Dr Yohann Loriot, Institut Gustave Roussy, France

Trial

Phase 3, LEAP-011

Conference

ASCO GU 2022

8 April, 2022 11:18

Sacituzumab govitecan effective in platinum-refractory metastatic urothelial cancer

Presented By

Dr Petros Grivas, University of Washington, WA, USA

Trial

Phase 2, TROPHY-U-01

Conference

ASCO GU 2022

8 April, 2022 11:16

DFS benefits with adjuvant pembrolizumab in RCC persist with longer follow-up

Presented By

Dr Toni Choueiri, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 3, KEYNOTE-564

Conference

ASCO GU 2022

8 April, 2022 11:14

Updates on pembrolizumab for oesophageal and gastric cancer

Presented By

Dr Jean-Philippe Metges, CHU Brest, France; Dr Zev Wainberg, University College Los Angeles, CA, USA

Trial

Phase 3, KEYNOTE-590, KEYNOTE-062

Conference

ASCO GI 2022

21 March, 2022 11:08

Pembrolizumab safe and efficacious in advanced hepatocellular carcinoma

Presented By

Prof. Shukui Qin, Nanjing University of Chinese Medicine, China

Trial

Phase 3, KEYNOTE-394

Conference

ASCO GI 2022

21 March, 2022 10:11

ASCO GU 2022 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ASCO GU 2022

14 March, 2022 07:21

ASCO GI 2022 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ASCO GI 2022

8 February, 2022 12:37

Neoadjuvant pembrolizumab plus chemotherapy benefits event-free survival in TNBC

Presented By

Prof. Peter Schmid, Barts Cancer Institute, UK

Trial

Phase 3, KEYNOTE-522

Conference

SABCS 2021

31 January, 2022 17:45

Pembrolizumab plus chemotherapy benefits patients with combined positive score ≥10

Presented By

Dr Javier Cortés, Vall d'Hebron Institute of Oncology, Spain

Trial

Phase 3, KEYNOTE-355

Conference

SABCS 2021

31 January, 2022 17:40

SABCS 2021 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

SABCS 2021

10 January, 2022 20:59

Double-positive results for triple-negative metastatic breast cancer

Presented By

Prof. Hope Rugo, University of California, San Francisco, USA

Trial

Phase 3, KEYNOTE-355

Conference

ESMO 2021

19 November, 2021 09:48

TCR clonality predicts pembrolizumab response in NSCLC

Presented By

Dr Afef Abed, Edith Cowan University, Australia

Conference

ESMO 2021

19 November, 2021 09:31

Adjuvant immunotherapy reduces risk of disease recurrence in stage II melanoma

Presented By

Dr Jason Luke, UPMC Hillman Cancer Center, PA, USA

Trial

Phase 3, KEYNOTE-716

Conference

ESMO 2021

19 November, 2021 09:30

Combining T-VEC and pembrolizumab does not significantly improve survival in advanced, unresectable melanoma

Presented By

Dr Helen Gogas, National and Kapodistrian University of Athens, Greece

Trial

Phase 3, MASTERKEY-265

Conference

ESMO 2021

19 November, 2021 09:30

Pembrolizumab prolongs survival in persistent, recurrent, or metastatic cervical cancer

Presented By

Prof. Nicoletta Colombo, Istituto Europeo di Oncologia, Italy

Trial

Phase 3, KEYNOTE-826

Conference

ESMO 2021

19 November, 2021 09:23

Pembrolizumab has durable effect in previously treated MSI-H/dMMR advanced endometrial cancer

Presented By

Prof. David O’Malley, Ohio State University, USA

Trial

Phase 2, KEYNOTE-158

Conference

ESMO 2021

19 November, 2021 09:23

Pembrolizumab shows potential in TKI-resistant EGFR+ NSCLC, not ALK+

Presented By

Prof. Shirish Gadgeel, University of Michigan, USA

Conference

WCLC 2021

21 September, 2021 13:24

KEYNOTE-564: First positive phase 3 results with adjuvant checkpoint inhibition in RCC

Presented By

Prof. Thomas Powles, Barts Cancer Centre, London, UK

Trial

Phase 3, KEYNOTE-564

Conference

EAU 2021

31 August, 2021 12:28

Pembrolizumab benefits survival in MSI-H/dMMR metastastic colorectal cancer

Presented By

Prof. Thierry André, Sorbonne University, France

Trial

Phase 3, KEYNOTE 177

Conference

ASCO 2021

12 August, 2021 23:32

Post-nephrectomy pembrolizumab improves disease-free survival

Presented By

Dr Toni Choueiri , Dana-Farber Cancer Institute, MA, USA

Trial

Phase 3, KEYNOTE 564

Conference

ASCO 2021

12 August, 2021 21:23

Promising efficacy and safety of feladilimab in recurrent/metastatic urothelial carcinoma

Presented By

Dr Arjun Balar , Perlmutter Cancer Center, NY, USA

Trial

Phase 1, INDUCE-1

Conference

ASCO 2021

12 August, 2021 12:30

Immuno-oncology agents are effective in treating classic Hodgkin’s lymphoma

Presented By

Dr Marc André, Centre Hospitalier Universitaire UCL Namur, Belgium

Trial

CheckMate 205; KEYNOTE-087

Conference

EHA 2021

5 August, 2021 12:26

CLEAR trial: promising new combination to treat RCC

Presented By

Dr Alain Ravaud, Centre Hospitalier Universitaire de Bordeaux, France

Trial

Phase 3, CLEAR

Journal

Physician’s Weekly

Conference

ASCO GU 2021

15 April, 2021 16:19

Chemoimmunotherapy is effective in a subset of small cell lung cancer patients

Presented By

Prof. Taofeek Owonikoko, Emory University School of Medicine

Trial

KEYNOTE-604, ECOG-ACRIN EA5161

Journal

Physician’s Weekly

Conference

ASCO20 Virtual Meeting

15 April, 2021 16:03

Lenvatinib plus pembrolizumab prolongs survival in renal cell carcinoma

Presented By

Dr Robert Motzer, Memorial Sloan Kettering Cancer Centre, New York, USA

Trial

Phase 3, CLEAR

Conference

ASCO GU 2021

24 March, 2021 14:53

First-line pembrolizumab shows superior PFS in MSI-H/dMMR mCRC

Presented By

Dr Kai-Keen Shiu, University College London Hospitals NHS Foundation Trust, UK

Trial

Phase 3, KEYNOTE-177

Conference

ASCO GI 2021

12 March, 2021 11:52

Neoadjuvant pembrolizumab in locally-advanced rectal cancer: primary results

Presented By

Dr Osama Rahma, Dana-Farber Cancer Institute, USA

Trial

Phase 2

Conference

ASCO GI 2021

12 March, 2021 11:46

Second-line pembrolizumab after progression on sorafenib benefits OS/PFS in advanced HCC

Presented By

Prof. Philippe Merle, University Hospital Lyon, France

Trial

Phase 3, KEYNOTE-240

Conference

ASCO GI 2021

12 March, 2021 11:37

Phase 2 study supports first-line pembrolizumab in advanced HCC

Presented By

Dr Jean-Luc van Laethem, Hôpital Erasme–Université Libre de Bruxelles, Belgium

Trial

Phase 2, KEYNOTE-224

Conference

ASCO GI 2021

12 March, 2021 11:35

First-line immune checkpoint inhibition in metastatic NSCLC

Conference

ESMO 2020

25 November, 2020 15:00

PD-L1 density, a new predictive biomarker in NSCLC

Conference

ESMO 2020

25 November, 2020 14:59

Adjuvant immune checkpoint inhibition after complete resection

Conference

ESMO 2020

25 November, 2020 14:55

Immuno-combination therapy in metastatic melanoma

Conference

ESMO 2020

25 November, 2020 14:52

First-line immune-combination therapies in mUC

Trial

Phase 3, KEYNOTE-361

Conference

ESMO 2020

25 November, 2020 14:43

Pembrolizumab as first-line in MSI-H mCRC

Expert

Prof. Thierry André, St Antoine Hospital, France

Trial

Phase 3, KEYNOTE-177

Conference

ASCO 2020

17 September, 2020 14:55

Pembrolizumab improves PFS for relapsed/refractory Hodgkin lymphoma

Presented By

Prof. Pier Luigi Zinzani, University of Bologna, Italy

Trial

Phase 3, KEYNOTE-204

Conference

EHA 2020

9 September, 2020 12:38

ES-SCLC: pembrolizumab KEYNOTE-604 data

Presented By

Dr Charles M. Rudin, Memorial Sloan Kettering Cancer Center, USA

Trial

Phase 3, KEYNOTE-604

Conference

ASCO 2020

8 September, 2020 13:20

Combination pembrolizumab/chemo improves PFS in metastatic TNBC

Presented By

Dr Javier Cortés & Catherine M. Kelly

Trial

KEYNOTE-355

Conference

ASCO 2020

8 September, 2020 09:32

Adjuvant pembrolizumab: durable RFS for stage III melanoma

Presented By

Prof. Alexander Eggermont, Princess Máxima Centre, NL

Trial

Phase 3, EORTC 1325-MG/KEYNOTE-054

Conference

ASCO 2020

28 August, 2020 15:45

Pembrolizumab plus low-dose ipilimumab well tolerated after progression on PD1 antibody therapy

Principal Investigator

Dr Daniel Olson, The University of Chicago Comprehensive Cancer Center, IL, USA

Trial

Phase 2

Conference

ASCO 2020

28 August, 2020 15:05

Understanding MIBC biology for novel treatment options

Presented By

Prof. Yohann Loriot, Université Paris-Saclay, France

Trial

BLC2001; THOR; EV-301; EV-302; TROPHY-U-01; RANGE

Conference

EAU 2020

20 August, 2020 12:36

KEYNOTE-426: no QoL differences pembrolizumab + axitinib versus sunitinib

Presented By

Prof. Jens Bedke, University of Tübingen, Germany

Trial

Phase 3, KEYNOTE-426

Conference

EAU 2020

20 August, 2020 10:41

Pembrolizumab leads to higher toxicity risk in obese melanoma patients

Presented By

Ms Surya Ravichandran, Duke University, USA

Conference

AAD 2020

6 August, 2020 07:03

Neoadjuvant + adjuvant pembrolizumab improves pCR in triple-negative breast cancer with lymph node involvement

Trial

KEYNOTE-173, Phase 1b ; I-SPY 2, Phase 2 ; KEYNOTE-522, Phase 3

Conference

SABCS 2019

13 February, 2020 22:56

Triple negative breast cancer gets positive news: KEYNOTE-522 interim results

Presented By

Prof. Peter Schmid, Queen Mary University of London, UK

Trial

Phase 3, KEYNOTE-522

Conference

ESMO 2019

26 November, 2019 23:12

Improved response rates without survival benefit with pembrolizumab in pretreated mesothelioma

Presented By

Dr Sanjay Popat, Royal Marsden Hospital NHS Foundation Trust, UK

Trial

PROMISE-meso

Conference

ESMO 2019

26 November, 2019 23:04

Enfortumab vedotin and pembrolizumab in advanced bladder cancer: initial results

Presented By

Prof. Christopher Hoimes, Case Comprehensive Cancer Center, Cleveland, USA

Trial

Phase 1, EV-103

Conference

ESMO 2019

26 November, 2019 22:23

First-line pembrolizumab monotherapy offers durable OS benefit vs chemotherapy in NSCLC patients with high PD-L1 expression

Presented By

Dr Martin Reck, Lung Clinic Grosshansdorf, Germany

Trial

KEYNOTE-024

Conference

WCLC 2019

8 November, 2019 23:23

Pembrolizumab + chemotherapy beneficial in advanced NSCLC, even without PD-L1 expression

Trial

KEYNOTE-021, KEYNOTE-189, KEYNOTE 407

Conference

WCLC 2019

8 November, 2019 22:57

pTMB is a feasible predictive biomarker for chemoimmunotherapy

Conference

WCLC 2019

8 November, 2019 21:58

KEYNOTE-062: Pembrolizumab combination fails to improve survival in gastric/GEJ cancer

Presented By

Dr Josep Tabernero, Vall d’Hebron University Hospital, Spain

Trial

Phase 3, KEYNOTE-062

Conference

ASCO 2019

15 July, 2019 22:56

Overcoming the challenges of immunotherapy in non–small cell lung cancer

Presented By

Dr Sarah B. Goldberg, Dr Melissa Lynne Johnson, Dr Alexander Chi

Trial

PACIFIC, KEYNOTE-024, KEYNOTE-189

Conference

ASCO 2019

15 July, 2019 22:04

Pembrolizumab monotherapy leads to 5-year survival in some patients with NSCLC

Presented By

Dr Edward B. Garon, David Geffen School of Medicine, USA

Trial

Phase 1, KEYNOTE-001

Conference

ASCO 2019

15 July, 2019 20:17

I-O monotherapy

Presented By

Prof. Martin Reck, Airway Research Center North, Grosshansdorf, Germany

Trial

CheckMate 026, Keynote-024, Checkmate 227, MYSTIC, B-F1RST

Conference

ELCC 2019

25 June, 2019 23:13

Combo I-O plus chemotherapy

Presented By

Dr Luis Paz-Ares, Complutense University of Madrid, Spain

Trial

Keynote-189, Impower-132

Conference

ELCC 2019

25 June, 2019 22:15

Immunotherapy in SCLC: trial data

Presented By

Dr Enriqueta Felip, Vall d’Hebron University Hospital, Spain

Trial

CA184-156, CheckMate-451, CASPIAN, Keynote-604, Checkmate 032

Conference

ELCC 2019

25 June, 2019 08:15

Updated interim results of phase 2 trial of pembrolizumab for high-risk NMIBC unresponsive to BCG

Presented By

Prof. Ashish Kamat, MD Anderson Cancer Center, Houston, USA

Trial

KEYNOTE-057, KEYNOTE-676

Conference

EAU 2019

21 May, 2019 17:01

Combination therapies: Where are we in 2018?

Presented By

Prof. Martin Reck, German Center for Lung Research, Germany

Conference

WCLC 2018

21 November, 2018 22:05

Choice of taxane and addition of pembrolizumab for metastatic squamous non-small-cell lung cancer

Presented By

Prof. Balazs Halmos, Albert Einstein College of Medicine and Montefiore Medical Center, USA

Trial

Phase 3, KEYNOTE-407

Conference

WCLC 2018

21 November, 2018 21:18